tci 2016 dutch clusters on stage

Titel presentatie[Naam, organisatienaam]

Working Day - Track: Modern cluster policyDutch clusters on stage

Ingrid Coninx, Hans Rijnten, Mirjam Mol & James Wilson

Dutch clusters on stage

Dutch Clusters on Stage

Ingrid Coninx, Wageningen Environmental ResearchHans Rijnten, Economic Board UtrechtMirjam Mol, Pivot ParkJames Wilson, Orkestra – Basque Institute of Competitiveness

Large variety

3

TCI GLOBAL CONFERENCE 2016Dutch clusters on the stage

Hans Rijnten, Economic Board Utrecht

November 10, 2016

Megatrend 1: Climate Change

Megatrend 2: Ageing population

Megatrend 3: Digitalisation

Economic Board UtrechtEconomic Research – our strenghts

Economic Board UtrechtTriple helix partners

• Societal challenge = economic opportunity

• Strategic agenda: o green economyo Life sciences & healtho Service innovation

• Private commitment (businesses)• Scalable• Reinforcement profile region

Economic Board UtrechtRegional agenda 2013-2020: Green, Healthy and Smart

EBU: Results 2015

Initiatief Bijdrage Vorm Omvang Spin off €

NOM; 033-Energy € 1,4 M Cofin. € 5 M € 90 M

Fiware € 0.94 M Cofin. € 2.64 M € 20 M

Dutch Game Garden € 0.750 M Cofin. € 2.25 M € 20 M

DGA - Control conference € 0.15 M Cofin. € 0.95 M € 2 M

‘Groen-gezond-slim’ fund € 1 M lening € 4 M PM.

NOMMIF € 0.55 M Cofin. € 0.675 M € 7,2 M

MIT-regelingen € 1 M Cofin. € 2 M € 6 MTotaal € 5,8 M variabel € 17,5 M € 145 M

www.pivotpark.com

Pivot ParkThe ecosystem

Mirjam Mol10 November 2016

● 13

Pivot Park is a unique park in the NetherlandsTHE place for innovative drug discovery research and development in the Netherlands: form target to market

Where chemistry and biology meet

Turn key facilities: state of the art laboratories, offices, completely furnished and equipped to start research or development activities

Unique core facilities: Modern equipment which is needed for biological, chemical and analytical lab research

two pilot plants

ultra high throughput screening facility with compound collection

R & D services (equipment / utilities / waste management) by a team of experts; customized solution for our customers

Cross-over Chemistry/Life Sciences

History

Analytics

HTSuHTSCompounds

Pilot Plants

Lab & Office facilities

• Fully equipped labs

• Open Access labs

• Flex labs

• Nuclear Magnetic Resonance

• Liquid Chromatography

• Mass Spectrometry

• Open Access HTS

• Flexible uHTS• Hit / Lead

optimization

• Up to 10 kg• GMP standard• Small

molecules• GMP/FDA

approved• Clinical trial

materials• Marketed

batches

Unieke faciliteiten, apparatuur, kennis en bedrijfsvoering

Growth of the Pivot Park Community

Pivot Park community (September 2016)

CROs

Product development

CMOs

Other services

Pivot Park community – R&D pathway (September 2016)

Acerta PharmaAPO-TAduro Biotech EuropeGlycostemInnatOssLead PharmaLitevaxModiquestNTRCOsteo-PharmaSynAffi x

3D-PharmXchangeAUTHOR!BioAxisBioXpertInProcess-LSPPivot Park Screening CentreSpinnovation AnalyticalQuality by DesignQuantitative SolutionsQuintilesZwiers Regulatory

AspenBioConnection ChemConnection

Arnold+Siedsma BAM Infra StruktonBogaerts en Groenen CVIS Thema groepDotcombusiness ESP Van Oss GroepFriday Life Sciences Hulshof Kroonen & GroenEkoy Investment Partners Rescop

RegistrationTarget discovery

Leaddiscovery

Leadoptimization

Pre-clinical development

Clinical phase I

Clinical phase II

Clinical phase III

Largescale manufacturing

Pivot Park CommunityBenefits of the ecosystem

• Inspiration by interaction• New opportunities for

collaboration• Diversity: from target to

market• Sharing high-end

facilities = cost reduction• Strong position in

regional, national and international knowledge infrastructure

Main trend in innovative entrepreneurship worldwide!

Facilitating open innovation

Closed innovatio

n

Open innovatio

n

From closed …

• Solo-creation• Transactions• IP legal drive• Academic research

funding by industry

• Large enterprises determine market access for innovation

… to open innovation:

• Co-creation• Networks/

Relationships• Entrepreneurial

drive• Commercial &

Academic research collaboration

• SMEs accelerate market access in innovation

Screening consortiaTKI Oncodrugs

TargetID HTS Hit

OptimisationLead Optimisation

DevelopmentCandidate

Clinical Development

Identification and development of compounds for different targets • NKI, NTRC, Covalution BioSciences and Lead Pharma targets• PPSC High Throughput Screening using their compound library• Leids Instituut voor Chemie (LIC) MedChem (in close collaboration with PPSC)• NKI testing • Lead Pharma, Covalution BioSciences and NTRC MedChem, H2L and LO

Objective: Find lead series/clinical candidates in the field of oncology and interest from big pharma

Covalution BioSciences